In this episode, Dr. Andrew Cutler interviews Dr. Joseph Goldberg on the management of metabolic side effects associated with antipsychotics.

Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click https://nei.global/POD21-MET

Learning Objectives: After completing this educational activity, you should be better able to:

Differentiate antipsychotic medications based on risk for metabolic side effects
Monitor patients for metabolic side effects
Implement management strategies to address metabolic side effects

Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NEI designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

A posttest minimum score of 70% is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics

Credit Types. The following are being offered for this activity:

Nurse Practitioner (ANCC): contact hours
Pharmacy (ACPE): application-based contact hours
Physician (ACCME): AMA PRA Category 1 Credits ™
Physician Assistant (AAPA): Category 1 CME credits
Psychology (APA): CE credits
Social Work (ASWB-ACE): ACE CE credits
Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™

Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.

Disclosures: All individuals in a position to influence or control content were required to disclose any relevant financial relationships, which were then mitigated prior to the activity being presented.

Interviewer

Andrew J. Cutler, MD

Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY

Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA

Consultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva

Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris

Interviewee

Joseph F. Goldberg, MD

Clinical Professor, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, NY

Consultant/Advisor: BioXcel, Intra-Cellular, Lundbeck, Otsuka, Sunovion

Speakers Bureau: Allergan/Abbvie, Intra-Cellular, Sage, Sunovion

Royalties: American Psychiatric Publishing, Cambridge University Press

Pre-Interview Author

Sabrina K. Bradbury-Segal, PhD

Medical Writer, Neuroscience Education Institute, Carlsbad, CA

No financial relationships to disclose.

The Planning Committee and Peer Reviewer have no financial relationships to disclose.

Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found here: https://nei.global/culture

Support: This activity is supported by an unrestricted educational grant from Intra-Cellular Therapies.

Released: December 22, 2021 CE credit expires: December 22, 2024

The Greatest Hits — Populist Edition. In conversation with Johannes Voelz